Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News CG Oncology, Inc.

Equities

CGON

US1569441009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
28.5 USD -5.06% Intraday chart for CG Oncology, Inc. -21.42% 0.00%
May. 09 CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 03 CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
AQ
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
CG Oncology, Inc. Announces Data from the Phase 3 BOND-003 Study Evaluating the Efficacy and Safety of Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette Guerin
CI
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
AQ
PACS Group to raise $450 mln in US IPO at over $3 bln valuation
RE
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
AQ
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CG Oncology, Inc.(NasdaqGS:CGON) added to S&P TMI Index
CI
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
AQ
Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target
MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target
MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55
MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target
MT
Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut
RE
Fractyl Health valued at $654.6 mln in tepid debut
RE
Fractyl Health prices US IPO below range to raise $110 mln
RE
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGON Stock
  4. News CG Oncology, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW